Scarica l'app Stockscreener
2.51
5.28%
-0.14
Pre-mercato:
2.54
0.03
+1.20%
Precedente Chiudi:
$2.65
Aprire:
$2.63
Volume 24 ore:
3.12M
Relative Volume:
0.61
Capitalizzazione di mercato:
$395.43M
Reddito:
$101.21M
Utile/perdita netta:
$-569.00K
Rapporto P/E:
-125.50
EPS:
-0.02
Flusso di cassa netto:
$-56.88M
1 W Prestazione:
+12.56%
1M Prestazione:
+212.97%
6M Prestazione:
+130.28%
1 anno Prestazione:
+47.65%
Intervallo 1D:
$2.45
$2.82
Intervallo di 1 settimana:
$2.10
$2.82
Portata 52W:
$0.40
$2.82
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Nome
Cytomx Therapeutics Inc
Settore
Industria
Telefono
650.515.3185
Indirizzo
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Confronta CTMX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
2.51 | 334.78M | 101.21M | -569.00K | -56.88M | -0.02 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | Ripresa | Piper Sandler | Overweight |
| 2024-05-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-05-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-04-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-11-14 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-07 | Downgrade | Mizuho | Buy → Neutral |
| 2022-07-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2022-01-18 | Aggiornamento | Barclays | Underweight → Overweight |
| 2021-11-15 | Iniziato | BTIG Research | Buy |
| 2021-05-28 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-03-29 | Iniziato | JP Morgan | Overweight |
| 2021-03-23 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-09-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-06-01 | Downgrade | Jefferies | Buy → Hold |
| 2020-05-14 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-24 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-03-04 | Iniziato | Barclays | Equal Weight |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-11-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-05-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-03-11 | Iniziato | Barclays | Overweight |
| 2018-11-26 | Iniziato | Piper Jaffray | Overweight |
| 2018-10-15 | Iniziato | Goldman | Neutral |
| 2018-09-13 | Iniziato | H.C. Wainwright | Buy |
| 2018-06-01 | Iniziato | SunTrust | Buy |
| 2018-01-05 | Iniziato | Citigroup | Buy |
| 2017-09-08 | Iniziato | Wedbush | Outperform |
| 2017-03-27 | Iniziato | H.C. Wainwright | Buy |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2017-01-03 | Downgrade | Oppenheimer | Outperform → Perform |
| 2015-11-02 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Cytomx Therapeutics Inc Borsa (CTMX) Ultime notizie
Millennium Management LLC Grows Stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
CytomX stock soars to 52-week high, hits $2.66 By Investing.com - Investing.com South Africa
CytomX stock soars to 52-week high, hits $2.66 - Investing.com Australia
CytomX Therapeutics CEO Set for Jefferies Conference: Key Biologics Updates Coming - Stock Titan
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference - TradingView
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story - simplywall.st
CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
CytomX Therapeutics (CTMX) Maintains "Buy" Rating with $5.00 Price Target | CTMX Stock News - GuruFocus
CytomX begins trial of new melanoma treatment with Merck therapy By Investing.com - Investing.com South Africa
CytomX begins trial of new melanoma treatment with Merck therapy - Investing.com Australia
CytomX (CTMX) Advances Phase 1 Study with CX-801 for Metastatic Melanoma | CTMX Stock News - GuruFocus
CytomX Therapeutics Doses First Patient in Phase 1 Study of CX-801 Combined with KEYTRUDA® for Metastatic Melanoma - Nasdaq
CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma - The Manila Times
Clinical Trial Breakthrough: CytomX's New Melanoma Drug Combines With Keytruda in Phase 1 Study - Stock Titan
Equities Analysts Set Expectations for CTMX Q2 Earnings - Defense World
What is HC Wainwright’s Estimate for CTMX FY2026 Earnings? - Defense World
CytomX upgraded at H.C. Wainwright on trial data for cancer drug - MSN
CytomX Therapeutics (NASDAQ:CTMX) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Upgraded by HC Wainwright - Defense World
CytomX Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st
H.C. Wainwright raises CytomX stock to buy, target to $5.00 By Investing.com - Investing.com South Africa
CytomX Therapeutics (CTMX) Price Target Raised by Piper Sandler - GuruFocus
CytomX Therapeutics (CTMX) Price Target Raised by Piper Sandler | CTMX Stock News - GuruFocus
After pivots and layoffs, CytomX Therapeutics smells success, $100 million payoff - The Business Journals
CytomX stock upgraded at H.C. Wainwright (CTMX:NASDAQ) - Seeking Alpha
HC Wainwright & Co. Upgrades CytomX Therapeutics (CTMX) - Nasdaq
CTMX Stock Rating Upgraded to Buy by HC Wainwright & Co. | CTMX - GuruFocus
H.C. Wainwright raises CytomX stock to buy, target to $5.00 - Investing.com
CTMX Stock Rating Upgraded to Buy by HC Wainwright & Co. | CTMX Stock News - GuruFocus
HC Wainwright Upgrades CytomX Therapeutics to Buy From Neutral, Price Target is $5 - marketscreener.com
CytomX Therapeutics (CTMX) Price Target Doubled Following Promis - GuruFocus
CTMX Stock Upgraded as New Clinical Data Shows Promise | CTMX St - GuruFocus
CytomX Therapeutics (CTMX) Price Target Doubled Following Promising Trial Results | CTMX Stock News - GuruFocus
CTMX Stock Upgraded as New Clinical Data Shows Promise | CTMX Stock News - GuruFocus
CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates - MSN
Institutional investors have a lot riding on CytomX Therapeutics, Inc. (NASDAQ:CTMX) with 52% ownership - simplywall.st
CytomX Therapeutics Stock (CTMX): Momentum from Promising Trials - Value The Markets
CytomX Therapeutics Secures $93.4 Million Through Stock Sale - TipRanks
CytomX Therapeutics: Doubling Overnight On Phase 1 Data... Still Bullish? - Seeking Alpha
CytomX Therapeutics jumps 54% after Q1 beat, prices $100M offering - MSN
CytomX (CTMX) Exceeds Revenue Expectations and Advances CRC Drug Development | CTMX Stock News - GuruFocus
CytomX Therapeutics Reports Q1 2025 Results and Progress - TipRanks
CytomX Therapeutics: Q1 Earnings Snapshot - MySA
CytomX Therapeutics Inc earnings beat by $0.21, revenue topped estimates - Investing.com South Africa
Transcript : CytomX Therapeutics, Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com
Latham & Watkins Advises CytomX Therapeutics on US$100 Million Underwritten Offering of Common Stock - Latham & Watkins LLP
CytomX Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
CytomX Therapeutics, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:CTMX) - Seeking Alpha
CytomX shares priced at $1.30 in $100 million offering By Investing.com - Investing.com South Africa
Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report - Benzinga
CytomX Shares Jump After Q1 Beat, 'Positive' Interim Trial Data - marketscreener.com
Cytomx Therapeutics Inc Azioni (CTMX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
6.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):